Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (11-20 of 195) with videos related to

Pageof 20
Sort By:
Clinical Breast Cancer|May 4, 2005
Clinical value of fulvestrant in breast cancerWilliam J Gradishar
Current Treatment Options in Oncology|February 22, 2003
Adjuvant systemic therapy of early stage breast cancerWilliam J Gradishar
Breast Cancer Research and Treatment|March 17, 2005
The future of breast cancer: the role of prognostic factorsWilliam J Gradishar
The New England Journal of Medicine|December 14, 2011
HER2 therapy--an abundance of richesWilliam J Gradishar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
No pain, no gain: a fallacy so farWilliam J Gradishar
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Albumin-bound nanoparticle paclitaxelWilliam J Gradishar
Expert Opinion on Pharmacotherapy|May 26, 2006
Albumin-bound paclitaxel: a next-generation taxaneWilliam J Gradishar
The New England Journal of Medicine|October 30, 2024
Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast CancerWilliam J Gradishar
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancerMary Cianfrocca, William J Gradishar
Clinical Breast Cancer|May 4, 2005
Current and future perspectives on fulvestrantWilliam J Gradishar, Tarek Sahmoud
Pageof 20

Showing results (11-20 of 195) with videos related to

Sort By:
Pageof 20
Clinical Breast Cancer|May 4, 2005
Clinical value of fulvestrant in breast cancerWilliam J Gradishar
Current Treatment Options in Oncology|February 22, 2003
Adjuvant systemic therapy of early stage breast cancerWilliam J Gradishar
Breast Cancer Research and Treatment|March 17, 2005
The future of breast cancer: the role of prognostic factorsWilliam J Gradishar
The New England Journal of Medicine|December 14, 2011
HER2 therapy--an abundance of richesWilliam J Gradishar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
No pain, no gain: a fallacy so farWilliam J Gradishar
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Albumin-bound nanoparticle paclitaxelWilliam J Gradishar
Expert Opinion on Pharmacotherapy|May 26, 2006
Albumin-bound paclitaxel: a next-generation taxaneWilliam J Gradishar
The New England Journal of Medicine|October 30, 2024
Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast CancerWilliam J Gradishar
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancerMary Cianfrocca, William J Gradishar
Clinical Breast Cancer|May 4, 2005
Current and future perspectives on fulvestrantWilliam J Gradishar, Tarek Sahmoud
Pageof 20